Project 1: Adjuvanted Protein Vaccines for Pandemic Preparedness

NIH RePORTER · NIH · U19 · $7,511,446 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract - Project 1: Adjuvanted Protein Vaccines for Pandemic Preparedness In preparation for possible future pandemics, our goals for Project 1 are to characterize immune responses and to develop new adjuvanted multivalent recombinant protein vaccines that are cross-protective within these target priority virus families with pandemic risk. We will interact closely with other Projects/Cores in the UCI ReVAMPP program. Each year we will supply Projects 3-5 and Translational Immunology Core with lead protein vaccine formulations for rodent and non-human primate immunity and challenge models and transitional human studies, as well as provide a protein microarray for antibody profiling in serum samples from all projects in the ReVAMPP programs. We will also support Project 2 on formulation and characterization of mRNA LNP candidates with various lipids, and collaborate with the Regulatory Science Core to ensure the work performed in this project meets the standards of a quality system allowing the rapid transfer of the recombinant protein vaccine technologies for their production and further IND-enabling studies. We propose five Specific Aims: (1) Adjuvant formulation and characterization for recombinant protein vaccines against Bunyaviruses, Paramyxoviruses and Picornaviruses (2) Immunoprofiling of multivalent recombinant protein vaccine formulations in rodents via i.m.; (3) To develop the process for the production of six recombinant protein vaccine antigen candidates against Bunyavirales, Paramyxoviridae, and Picornaviridae. (4) Protein vaccines for systemic and mucosal immunity. (5) Breadth/durability of multivalent protein vaccine formulations.

Key facts

NIH application ID
10863342
Project number
1U19AI181968-01
Recipient
UNIVERSITY OF CALIFORNIA-IRVINE
Principal Investigator
Li Liang
Activity code
U19
Funding institute
NIH
Fiscal year
2024
Award amount
$7,511,446
Award type
1
Project period
2024-08-20 → 2027-07-31